Ligand Pharmaceuticals: Dominance in the Biopharma Royalty Market – Licensing Revenues Expected to Increase by 23% Annually by 2030!

Ligand Pharmaceuticals stands out in the biopharmaceutical industry with a high-margin, low-risk licensing model in a Royalty market worth over $29 billion. Key products like Filspari and Ohtuvayre, along with the newly raised forecast for 2026, are expected to boost licensing revenues by an average of 23% per year until 2030. With $1 billion in available capital, further investments in new drug candidates can secure growth for the coming decades. Ligand Pharmaceuticals (LGND) operates as a highly profitable biopharma...